뒤로
Phathom Pharmaceuticals Inc (PHAT) 수입
PHAT 주가 차트
PHAT 수입
Phathom Pharmaceuticals Inc
$11.11
5.5%
$0.58
종가: Mar 31, 16:00:00 GMT-4
$11.2
0.81%
$0.08
프리마켓: Apr 01, 06:41:40 GMT-4
최신 수익 결과: Q4 '25
보고됨: 2026-02-26
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
PHAT의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Phathom Pharmaceuticals Inc PHAT의 지난 분기 매출 실적은 어땠나요?
Phathom Pharmaceuticals Inc의 매출 추정치는 얼마인가요?
Phathom Pharmaceuticals Inc의 수익 품질 점수는 얼마인가요?
Phathom Pharmaceuticals Inc는 언제 수익을 보고하나요?
Phathom Pharmaceuticals Inc의 예상 수익은 얼마인가요?
Phathom Pharmaceuticals Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$10.53
시가
$10.89
일일 범위
$10.75 - $11.31
52주 범위
$2.21 - $18.31
거래량
1.2M
평균 거래량
1.1M
배당수익률
--
EPS(TTM)
-3.81
시가총액
$882.5M
PHAT란 무엇인가요?
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 371 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.